Determinants of Maternal Triglycerides in Women With Gestational Diabetes Mellitus in the Metformin in Gestational Diabetes (MiG) Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Factors associated with increasing maternal triglyceride concentrations in late pregnancy include gestational age, obesity, preeclampsia, and altered glucose metabolism. In a subgroup of women in the Metformin in Gestational Diabetes (MiG) trial, maternal plasma triglycerides increased more between enrollment (30 weeks) and 36 weeks in those treated with metformin compared with insulin. The aim of this study was to explain this finding by examining factors potentially related to triglycerides in these women. RESEARCH DESIGN AND METHODS: Of the 733 women randomized to metformin or insulin in the MiG trial, 432 (219 metformin and 213 insulin) had fasting plasma triglycerides measured at enrollment and at 36 weeks. Factors associated with maternal triglycerides were assessed using general linear modeling. RESULTS: Mean plasma triglyceride concentrations were 2.43 (95% CI 2.35–2.51) mmol/L at enrollment. Triglycerides were higher at 36 weeks in women randomized to metformin (2.94 [2.80–3.08] mmol/L; +23.13% [18.72–27.53%]) than insulin (2.65 [2.54–2.77] mmol/L, P = 0.002; +14.36% [10.91–17.82%], P = 0.002). At 36 weeks, triglycerides were associated with HbA1c (P = 0.03), ethnicity (P = 0.001), and treatment allocation (P = 0.005). In insulin-treated women, 36-week triglycerides were associated with 36-week HbA1c (P = 0.02), and in metformin-treated women, they were related to ethnicity. CONCLUSIONS: At 36 weeks, maternal triglycerides were related to glucose control in women treated with insulin and ethnicity in women treated with metformin. Whether there are ethnicity-related dietary changes or differences in metformin response that alter the relationship between glucose control and triglycerides requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Self-citationThe randle cycle revisited: a new head for an old hat.
Hue, L., & Taegtmeyer, H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00093.2009 · Cited by 743 · cited 1×
“Maternal glucose control and the pharmacological therapies used for treatment of GDM have the potential to influence these changes in maternal lipids (11).”
BackgroundIncreased fetal adiposity: a very sensitive marker of abnormal in utero development
Catalano, P. M., Thomas, A., Huston-Presley, L., & Amini, S. B. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(03)00828-7 · Cited by 519
Schaefer-Graf, U. M., Graf, K., Kulbacka, I., Kjos, S. L., Dudenhausen, J., Vetter, K., & Herrera, E. (2008) · Diabetes Care · doi:10.2337/dc08-0039 · Cited by 439 · cited 1×
“0 mmol/L, managed with diet or insulin therapy) during the late second (8–10,20) and late third trimester (8,20,21).”
BackgroundMetabolic Effects of Hypocaloric Diets in Management of Gestational Diabetes
Knopp, R. H., Magee, M. S., Raisys, V., & Benedetti, T. (1991) · Diabetes · doi:10.2337/diab.40.2.s165 · Cited by 72
Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin
Abbasi, F., Carantoni, M., Chen, Y. D. I., & Reaven, G. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1301 · Cited by 72
Cited by
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158
Egan, A. M., Dennedy, M. C., Al-Ramli, W., Heerey, A., Avalos, G., & Dunne, F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2684 · Cited by 125
“Nonetheless, encouraging data have supported the safety profile of metformin use with or without supplemental insulin in women with GDM, with some studies suggesting increased insulin sensitivity and improved longer-term outcomes in offspring (29, 31, 32).”
BackgroundA cautionary response to SMFM statement: pharmacological treatment of gestational diabetes
Barbour, L. A., Scifres, C., Valent, A. M., Friedman, J. E., Buchanan, T. A., Coustan, D., Aagaard, K., Thornburg, K. L., Catalano, P. M., Galan, H. L., et al. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.06.013 · Cited by 101
Feng, Y., & Yang, H. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1228061 · Cited by 68
Metformin versus insulin for gestational diabetes mellitus: a meta-analysis
Zhao, L., Sheng, X., Zhou, S., Yang, T., Ma, L., Zhou, Y., & Cui, Y. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12672 · Cited by 63
Li, G., Zhao, S., Cui, S., Li, L., Xu, Y., & Li, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3566-0 · Cited by 54
Metformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach
Barbour, L. A., & Feig, D. S. (2019) · Diabetes Care · doi:10.2337/dci18-0055 · Cited by 44
“(33), and it should not be used if the fetus is at risk for an ischemic environment including placental insufficiency, hypertension, preeclampsia, or growth restriction (12,13,15,16).”
Background
Metadata
- Authors
- Barrett, H. L., Dekker Nitert, M., Jones, L., O’Rourke, P., Lust, K., Gatford, K. L., De Blasio, M. J., Coat, S., Owens, J. A., Hague, W. M., McIntyre, H. D., Callaway, L., & Rowan, J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-06-12
- Volume
- 36
- Issue
- 7
- Pages
- 1941-1946
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2142458347
- Cited by
- 28
- References
- 6
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.